Dr. Reddy's endorses the launch of new Covid-19 medicine Remdesivir in India
By Jahanbee Gupta
Amid the persistent rise in COVID-19 cases in India, medicines beneficial in the treatment of the novel coronavirus are being developed in the country. In the last few months, medicines such as dexamethasone, favipiravir, corovir among others have been trumpeted for the treatment of the infection.
In the latest development, Dr. Reddys Laboratories Ltd on Wednesday, launched, Remdesivir, meant for the treatment of COVID-19 patients, under a brand name ‘Redux’ in India. Earlier, Dr. Reddy’s had also launched a drug named Avigan for Covid-19 treatment which consisted of the antiviral drug favipiravir. The said medicine is available for Rs. 99 per tablet and is used on coronavirus patients with mild and moderated symptoms. Avigan was manufactured by Japanese drug giant Fujifilm Toyama Chemical Co. Some corona patients were given Remdesivir medicine whereas some patients were treated by Placebo or alternative treatment.
Head of NIAID, Anthony Fauci, said, “it has been seen that Remdesivir medicine has reduced recovery time in patients. That means patients are recovering quickly. The results show that the drug is effective in fighting with this virus. This opened the door to the possibility of treating corona patients."